* Received regulatory and ethical approvals for clinical trial investigating IMP321 in new settings, called Insight​

* Approval has been received from Paul-Ehrlich-Institut, Federal Institute For Vaccines And Biomedicines For German Federal Ministry Of Health Source text for Eikon: Further company coverage: